表紙:頭頸部扁平上皮がん市場:KOLの洞察
市場調査レポート
商品コード
1682207

頭頸部扁平上皮がん市場:KOLの洞察

KOL Insight - Head and Neck Squamous Cell Carcinoma


出版日
ページ情報
英文
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
頭頸部扁平上皮がん市場:KOLの洞察
出版日: 2025年03月17日
発行: FirstWord Group
ページ情報: 英文
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

当レポートは、進化する頭頸部扁平上皮がん(HNSCC)の治療状況について、新規治療と臨床試験結果の統合に焦点を当て、詳細に分析しています。主な調査結果には、Merckのキイトルーダの期待される拡大、Merusの二重特異性抗体ペトセムタマブの可能性などが含まれます。また、Bicaraの二重機能抗体ficerafusp alfaの有望な初期データ、Summit/Akesoの二重特異性抗体ivonescimabの変革の可能性についても調査しています。これらの開発と将来のHNSCC治療への影響について、主なオピニオンリーダーから貴重な洞察を得ることができます。

レポートの内容

  • KEYNOTE-689試験の成功を受け、KOLはMerckのキイトルーダが局所進行(LA)HNSCC治療の周術期における新たな標準治療になるか
  • Merusの抗EGFR/LGR5 二重特異性抗体とキイトルーダの併用療法の初期データは、再発・転移性(R/M)HNSCCの一次治療において高い奏効率を示しているが、KOLはこのデータが良好な第III相試験につながるとどの程度楽観視しているか
  • SummitとAkesoは抗PD-1/VEGF二重特異性抗体ivonescimabの肺がんにおける印象的な臨床データを示しているが、専門家はHNSCCにおける見込みをどのように評価しているか
  • Coherus/JunshiのPD-1阻害剤Loqtorzi(toripalimab)がR/M上咽頭がん(NPC)でFDAとEMAから承認されたが、このPD-1阻害剤の中長期的な使用についてKOLはどのように期待しているか
  • KOLは、R/M HNSCC患者を対象としたCue BiopharmaのCUE-101の第Ⅱ相データをどのように解釈し、このIL-2ベースのT細胞エンゲージャーの成功の見込みをどのように評価しているか
  • 治療用ワクチンが将来のHNSCCの治療においてどのような役割を果たす可能性があるか

主要ブランド

  • キイトルーダ(ペムブロリズマブ)
  • オプジーボ(ニボルマブ)
  • ロクトルツィ(トリパリマブ)
  • ジェンペルリ(ドスタリマブ)
  • ペトセムタマブ(MCLA-158)
  • アイボネシマブ(SMT112/AK112)
  • ボルストミグ(MEDI5752)
  • フィセラフスプアルファ(BCA101)
  • エボパセプト(ALX148)
  • バーサムネHPV(PDS0101)
  • IO102-IO103
  • CUE-101
  • Inbrx-106(es-102)
  • エフティラギモドα(IMP321)
  • ASP-1929(セツキシマブ・サロタロカン)
  • AN2025(ブパルリシブ)
目次

This comprehensive report provides an in-depth analysis of the evolving treatment landscape for head and neck squamous cell carcinoma (HNSCC), focusing on the integration of novel therapies and clinical trial outcomes. Key findings include the anticipated expansion of Merck's Keytruda and the potential of Merus' bispecific antibody petosemtamab. This report also explores the promising early data for Bicara's bifunctional antibody ficerafusp alfa and the transformative potential of Summit/Akeso's bispecific ivonescimab. Gain valuable insights from key opinion leaders into these developments and their implications for future HNSCC treatment.

Key Questions Answered:

  • 1. Given the success of the KEYNOTE-689 study, do KOLs see Merck & Co.'s Keytruda becoming a new standard of care in the perioperative setting for the treatment of locally advanced (LA)-HNSCC?
  • 2. Early data for Merus' anti-EGFR/LGR5 bispecific antibody in combination with Keytruda indicate high response rates in first-line recurrent/metastatic (R/M) HNSCC, but how optimistic are KOLs that this could translate into a positive Phase III trial?
  • 3. While Summit and Akeso have shown impressive clinical data for their anti-PD-1/VEGF bispecific antibody ivonescimab in lung cancer, how do experts weigh up its prospects in HNSCC?
  • 4. With the FDA and EMA approvals of Coherus/Junshi's PD-1 inhibitor Loqtorzi (toripalimab) in R/M nasopharyngeal carcinoma (NPC), what are KOL expectations for this PD-1 inhibitor's use in the mid-to-long term?
  • 5. How do KOLs interpret the Phase II data for Cue Biopharma's CUE-101 in patients with R/M HNSCC, and how do they rate this IL-2-based T-cell engager's prospects for success?
  • 6. What is the likelihood that therapeutic vaccines will have a role in the future treatment of HNSCC?

Key Brands:

  • Keytruda (pembrolizumab)
  • Opdivo (nivolumab)
  • Loqtorzi (toripalimab)
  • Jemperli (dostarlimab)
  • petosemtamab (MCLA-158)
  • ivonescimab (SMT112/AK112)
  • volrustomig (MEDI5752)
  • ficerafusp alfa (BCA101)
  • evorpacept (ALX 148)
  • Versamune HPV (PDS0101)
  • IO102-IO103
  • CUE-101
  • INBRX-106 (ES-102)
  • eftilagimod alpha (IMP321)
  • ASP-1929 (cetuximab sarotalocan)
  • AN2025 (buparlisib)

Partial List of Participating Experts:

  • Professor, Medical Oncologist specialising in head and neck cancer, University of California, USA
  • Director of Head and Neck Medical Oncology and Professor of Medicine at the Marlene and Stewart Greenebaum Comprehensive Cancer Center, USA
  • Professor of Medicine and Head and Neck Oncologist, Duke Cancer Institute, USA
  • Head of Medical Oncology, Institut Catala d'Oncologia (ICO), Spain
  • Professor of Medical Oncology, Humanitas University, Italy
  • Consultant Clinical Oncologist and Honorary Reader, Royal Marsden Hospital and the Institute of Cancer Research, UK

Methodology

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.